Auxilium

2014 Press Releases

Webcast ImageWebcast
Q1 2014 Auxilium Pharmaceuticals, Inc. Earnings Conference Call (Replay)
May 5, 2014 at 8:30 a.m. ET
Webcast ImageWebcast
Auxilium Pharmaceuticals, Inc. Conference Call Announcing Merger with QLT (Replay)
Jun 26, 2014 at 8:30 a.m. ET
Keyword Search
 

Below please find a listing of the most recent Auxilium press releases.

DateTitle 
Jun 26, 2014Auxilium Pharmaceuticals to Merge with Canadian Biotechnology Company QLT
Accelerates Auxilium's Ongoing Transformation Into Leading North American Specialty Biopharmaceutical Company Canadian-Domiciled Structure Creates Stronger Financial Position, Competitive Partnering and M&A Platform Platform Enables Continued Product and Therapeutic Diversification; Expands Geographic Footprint CHESTERBROOK, Pa. and VANCOUVER, Canada, June 26, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company... 
Printer Friendly Version
Jun 25, 2014Sobi files for EU approval of Xiapex for Peyronies disease
STOCKHOLM and CHESTERBROOK, Pa., June 25, 2014 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi) and Auxilium Pharmaceuticals, Inc. today announced that Sobi has filed for an extension of the label for Xiapex® (collagenase clostridium histolyticum) with the European Medicines Agency (EMA) to include the indication of Peyronie's disease. The filing is based on positive safety and efficacy outcome data from two double-blind placebo-controlled studies, IMPRESS I and II (The Investigation... 
Printer Friendly Version
Jun 11, 2014Auxilium Pharmaceuticals, Inc. Announces Launch Of Authorized Generic Version Of Testim (Testosterone Gel)
CHESTERBROOK, Pa., June 11, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that it has partnered with Prasco, LLC ("Prasco") to introduce an Authorized Generic version of Testim® (testosterone gel). Prasco has product inventory available and has commenced shipping product. Testim and its Authorized Generic version are testosterone gels approved by the U.S. Food and Drug Administration to treat adult male... 
Printer Friendly Version
Jun 2, 2014Auxilium Pharmaceuticals, Inc. Announces Departure of Chief Financial Officer
CHESTERBROOK, Pa., June 2, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that James E. Fickenscher, Chief Financial Officer, is leaving the Company to pursue other interests. Mr. Fickenscher will continue in his current role through August 15, 2014. "The Board and I want to thank Jim for his nine years of service and important contributions to the evolution of Auxilium," said Adrian Adams, Chief Exe... 
Printer Friendly Version
May 30, 2014Auxilium Pharmaceuticals, Inc. To Present At The Jefferies Healthcare Conference
CHESTERBROOK, Pa., May 30, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that certain members of the executive management team will participate in the Jefferies Healthcare Conference to be held June 2-5, 2014 in New York. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product portfolio Company at 10:00 a.m. ET on Tuesday, June 3, 2014. ... 
Printer Friendly Version
May 19, 2014Auxilium Pharmaceuticals, Inc. Presents New Analyses Of XIAFLEX Peyronie's Disease Data At Urology Meeting
Four Podium Sessions Highlight New Analyses of Data Evaluating XIAFLEX for the Treatment of Peyronie's Disease CHESTERBROOK, Pa., May 19, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that new analyses of data were presented from its clinical program and pivotal IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) trials, the Phase 3 studies that evaluated XIAFLE... 
Printer Friendly Version
May 12, 2014Auxilium Pharmaceuticals, Inc. To Present At The UBS Healthcare Conference
CHESTERBROOK, Pa., May 12, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that certain members of the executive management team will participate in the UBS Healthcare Conference to be held May 19-21, 2014 at the Sheraton Times Square in New York. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product portfolio at 11:00 a.m. ET on Monday, Ma... 
Printer Friendly Version
May 7, 2014Auxilium Pharmaceuticals, Inc. To Present At The Bank Of America Merrill Lynch Healthcare Conference
CHESTERBROOK, Pa., May 7, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that certain members of the executive management team will participate in the Bank of America Merrill Lynch Healthcare Conference to be held May 13-15, 2014 at the Wynn Hotel in Las Vegas. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product portfolio at 9:20 a.... 
Printer Friendly Version
May 5, 2014Auxilium Pharmaceuticals, Inc. Announces First Quarter 2014 Financial Results
1Q 2014 Net Revenues Increased 34% Over 1Q 2013 to $88.5 Million on Acquisition Growth and Launch Momentum for STENDRA and XIAFLEX in Peyronie's Disease CHESTERBROOK, Pa., May 5, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced financial results for the first quarter ending March 31, 2014. The Company highlighted important commercial, regulatory and clinical development updates from the quarter and... 
Printer Friendly Version
May 1, 2014Auxilium Pharmaceuticals, Inc. to Present at the Deutsche Bank Healthcare Conference
CHESTERBROOK, Pa., May 1, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that certain members of the executive management team will participate in the Deutsche Bank Healthcare Conference to be held May 7-8, 2014 at the InterContinental Hotel in Boston. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product portfolio at 8:40 a.m. ET on Thurs... 
Printer Friendly Version
Apr 29, 2014Auxilium Pharmaceuticals, Inc. Lowers 2014 Financial Guidance
Company to Report Full 1Q 2014 Financial Results on Monday, May 5 CHESTERBROOK, Pa., April 29, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that it is reducing its financial guidance for the full year 2014 due primarily to lower-than-expected revenues from Testim® testosterone gel. Auxilium's revised financial guidance is as follows ($ millions): Revised Original ... 
Printer Friendly Version
Apr 28, 2014Auxilium Pharmaceuticals, Inc. Announces Presentation Of Data For XIAFLEX At Urology Meeting
Four Podium Sessions to Highlight New Analyses of Data from Pivotal Phase 3 Trials Evaluating XIAFLEX for the Treatment of Peyronie's Disease CHESTERBROOK, Pa., April 28, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced presentations from multiple trials evaluating the use of XIAFLEX® (collagenase clostridium histolyticum or CCH) in patients with Peyronie's disease (PD).These data will be present... 
Printer Friendly Version
Apr 14, 2014Auxilium and Sobi Announce Encore Presentation of XIAFLEX/Xiapex Data at European Association of Urology Congress
Encore Data Highlighted from Trials Evaluating XIAFLEX, the First and Only FDA Approved Treatment for Peyronie's Disease CHESTERBROOK, Pa. and STOCKHOLM, April 14, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) and Swedish Orphan Biovitrum AB (publ) (Sobi) today announced that encore data were presented from multiple clinical trials evaluating the use of XIAFLEX®/ Xiapex® (collagenase clostridium histolyticum or CCH) in adult patients with Peyronie's disease (PD). These ... 
Printer Friendly Version
Apr 7, 2014Sobi Becomes Market Authorisation Holder For Xiapex in Europe
STOCKHOLM and CHESTERBROOK, Pa., April 7, 2014 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi) and Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) today announced  that Sobi became the Market Authorisation Holder (MAH) for Xiapex® (collagenase clostridium histolyticum), in 28 EU member countries, Norway, and Iceland on April 3, 2014. Xiapex/ XIAFLEX® is a first-in-class biologic approved in the US, EU, Canada and Australia for the treatment of adult Dupuytren's contracture patients w... 
Printer Friendly Version
Mar 4, 2014Auxilium Pharmaceuticals, Inc. To Present At The Barclay's Global Healthcare Conference
CHESTERBROOK, Pa., March 4, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that certain members of the executive management team will participate in the Barclay's Global Healthcare Conference to be held March 11-13, 2014 at the Loews Hotel in Miami. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product portfolio at 3:45 p.m. ET on Tuesday,... 
Printer Friendly Version
Feb 28, 2014Auxilium Pharmaceuticals Announces Fourth Quarter And Full Year 2013 Financial Results And Guidance For 2014
FY 2013 Net Revenues of $400.7 Million, a 32% Increase Over 2012 Non-GAAP Net Revenues FY 2013 Non-GAAP EPS Grew 77% to $0.62 2014 Guidance for Net Revenues of $450 - $490 Million CHESTERBROOK, Pa., Feb. 28, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced financial results for the fourth quarter and full year ending December 31, 2013. The Company also highlighted select commercial, regulatory a... 
Printer Friendly Version
Feb 25, 2014Auxilium Pharmaceuticals, Inc. To Present At The Cowen And Company Annual Healthcare Conference
CHESTERBROOK, Pa., Feb. 25, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that certain members of the executive management team will participate in the Cowen and Company 34th Annual Healthcare Conference to be held March 3-5, 2014 at the Boston Marriott Copley Place Hotel in Boston. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and its produ... 
Printer Friendly Version
Feb 24, 2014Auxilium Pharmaceuticals, Inc. Announces The FDA Acceptance Of Application Requesting Approval Of XIAFLEX® For The Concurrent Treatment Of Multiple Palpable Cords
PDUFA Date Scheduled for October 20, 2014 CHESTERBROOK, Pa., Feb. 24, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's submission of a supplemental Biologics License Application (sBLA) requesting approval of XIAFLEX (collagenase clostridium histolyticum, or CCH) for the treatment of two  Dupuytren's contracture (DC) cords conc... 
Printer Friendly Version
Feb 21, 2014Auxilium Pharmaceuticals, Inc. To Announce Fourth Quarter And Full Year 2013 Results On February 28, 2014
-Company to Host Conference Call That Day at 9 a.m. ET- CHESTERBROOK, Pa., Feb. 21, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that the Company will release results for the fourth quarter and full year 2013 on Friday, February 28, 2014 before the opening of the U.S. financial markets. The Company also will conduct a conference call that day at 9 a.m. ET to discuss results and highlights of the f... 
Printer Friendly Version
Feb 19, 2014Auxilium Pharmaceuticals, Inc. To Present At The RBC Capital Markets Healthcare Conference
CHESTERBROOK, Pa., Feb. 19, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that certain members of the executive management team will participate in the RBC Capital Markets Healthcare Conference to be held February 25-26, 2014 at the New York Palace Hotel in New York. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product portfolio at 1:35 ... 
Printer Friendly Version
Feb 19, 2014Auxilium Pharmaceuticals, Inc. To Ring the NASDAQ Stock Market Opening Bell On February 26, 2014
-Company Marks Milestone of Two New Product Launches- CHESTERBROOK, Pa., Feb. 19, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, will ring the Opening Bell at the NASDAQ MarketSite in Times Square, New York at 9:30 a.m. ET on February 26, 2014 to celebrate Auxilium's transformation into a leading men's healthcare company, including two recent launches of new products in men's healthcare, XIAFLEX® (collagenase cl... 
Printer Friendly Version
Feb 5, 2014Auxilium Pharmaceuticals, Inc. To Present At The Leerink Swann Global Healthcare Conference
CHESTERBROOK, Pa., Feb. 5, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that certain members of the executive management team will participate in the Leerink Swann Global Healthcare Conference to be held February 11-13, 2014 at the Waldorf Astoria Hotel in New York. Adrian Adams, Chief Executive Officer and President, is scheduled to participate in a discussion about the Company at 10:40 a.m. ET on Wed... 
Printer Friendly Version
Feb 3, 2014Auxilium Pharmaceuticals, Inc. To Present At The BIO CEO & Investor Conference
CHESTERBROOK, Pa., Feb. 3, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that certain members of the executive management team will participate in the BIO CEO & Investor Conference to be held February 10-11, 2014 at the Waldorf Astoria Hotel in New York. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product portfolio at 9 a.m. ET on M... 
Printer Friendly Version
Jan 21, 2014VIVUS and Auxilium Announce FDA Acceptance of Supplemental Filing Seeking an Update of Prescribing Information for STENDRA (avanafil)
MOUNTAIN VIEW, Calif. and CHESTERBROOK, Pa., Jan. 21, 2014 /PRNewswire/ -- VIVUS, Inc. (Nasdaq: VVUS) and Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) today announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental application that proposes to revise the STENDRA™ (avanafil) prescribing information with efficacy and safety information from Study TA-501, entitled "A Randomized, Double-Blind, Placebo-Controlled Evaluation of Avanafil for On-Demand Treatment of Men with... 
Printer Friendly Version
Jan 8, 2014Auxilium Pharmaceuticals, Inc. To Present At The J.P. Morgan 32nd Annual Healthcare Conference
CHESTERBROOK, Pa., Jan. 8, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that the executive management team will participate in the J.P. Morgan 32nd Annual Healthcare Conference to be held January 13-16, 2014 at the Westin St. Francis Hotel in San Francisco. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product portfolio at 4 p.m. PT on W... 
Printer Friendly Version
Jan 8, 2014Auxilium Pharmaceuticals Presents Interim Data on XIAFLEX® for the Retreatment of Recurring Dupuytren's Contracture at the American Association for Hand Surgery 2014 Annual Meeting
Data Show Recurrent Hand Contractures Treated Successfully in Nearly 90 Percent of Patients; Retreatment Shown to be Well-Tolerated CHESTERBROOK, Pa., Jan. 8, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that interim data from its Phase 4 retreatment study (AUX-CC-862) evaluating XIAFLEX® (collagenase clostridium histolyticum or CCH) in adult patients with Dupuytren's contracture (DC) and a rec... 
Printer Friendly Version